DE60333260D1 - Histone-deacetylase-inhibitoren - Google Patents

Histone-deacetylase-inhibitoren

Info

Publication number: DE60333260D1
Authority: DE; Germany
Prior art keywords: inhibitoren; deacetylase; histone
Prior art date: 2002-03-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60333260T

Other languages

English (en)

Inventor

Emelen Kristof Van

Marc Gustaaf Celine Verdonck

Brandt Sven Franciscus Anna Van

Patrick Rene Janssen-Cila Angibaud

Lieven Meerpoel

Alexey Borisovich Dyatkin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Pharmaceutica NV

Original Assignee

Janssen Pharmaceutica NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-13

Filing date

2003-03-11

Publication date

2010-08-19

2003-03-11 Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV

2010-08-19 Application granted granted Critical

2010-08-19 Publication of DE60333260D1 publication Critical patent/DE60333260D1/de

2023-03-12 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
General Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)

DE60333260T 2002-03-13 2003-03-11 Histone-deacetylase-inhibitoren Expired - Lifetime DE60333260D1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US36379902P	2002-03-13	2002-03-13
PCT/EP2003/002515 WO2003075929A1 (en)	2002-03-13	2003-03-11	Inhibitors of histone deacetylase

Publications (1)

Publication Number	Publication Date
DE60333260D1 true DE60333260D1 (en)	2010-08-19

Family

ID=27805289

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DE60326436T Expired - Lifetime DE60326436D1 (en)	2002-03-13	2003-03-11	Aminoderivate als histone-deacetylase-inhibitoren
DE60326549T Expired - Lifetime DE60326549D1 (en)	2002-03-13	2003-03-11	Aminocarbonylderivate als histone-deacetylase-inhibitoren
DE60333260T Expired - Lifetime DE60333260D1 (en)	2002-03-13	2003-03-11	Histone-deacetylase-inhibitoren

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DE60326436T Expired - Lifetime DE60326436D1 (en)	2002-03-13	2003-03-11	Aminoderivate als histone-deacetylase-inhibitoren
DE60326549T Expired - Lifetime DE60326549D1 (en)	2002-03-13	2003-03-11	Aminocarbonylderivate als histone-deacetylase-inhibitoren

Country Status (26)

Country	Link
US (16)	US7816363B2 (de)
EP (4)	EP1485099B1 (de)
JP (4)	JP4644428B2 (de)
KR (2)	KR20040090979A (de)
CN (2)	CN1642551B (de)
AR (1)	AR039566A1 (de)
AT (4)	ATE425152T1 (de)
AU (4)	AU2003212335B8 (de)
BR (2)	BR0308081A (de)
CA (4)	CA2475764C (de)
DE (3)	DE60326436D1 (de)
DK (1)	DK1485353T3 (de)
EA (2)	EA007272B1 (de)
ES (4)	ES2322950T3 (de)
HK (1)	HK1078473A1 (de)
HR (2)	HRP20040799A2 (de)
IL (7)	IL164003A0 (de)
MX (2)	MXPA04008806A (de)
NO (2)	NO20044113L (de)
NZ (2)	NZ534834A (de)
OA (2)	OA12791A (de)
PL (2)	PL213783B1 (de)
TW (1)	TW200400822A (de)
UA (4)	UA77263C2 (de)
WO (4)	WO2003076400A1 (de)
ZA (6)	ZA200407235B (de)

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6951862B2 (en)	1998-06-30	2005-10-04	Neuromed Technologies, Inc.	Calcium channel blockers comprising two benzhydril moieties
US7186726B2 (en)	1998-06-30	2007-03-06	Neuromed Pharmaceuticals Ltd.	Preferentially substituted calcium channel blockers
US7868204B2 (en)	2001-09-14	2011-01-11	Methylgene Inc.	Inhibitors of histone deacetylase
US7595343B2 (en)	2001-09-14	2009-09-29	Methylgene, Inc.	Inhibitors of histone deacetylase
US6897220B2 (en)	2001-09-14	2005-05-24	Methylgene, Inc.	Inhibitors of histone deacetylase
US7390813B1 (en)	2001-12-21	2008-06-24	Xenon Pharmaceuticals Inc.	Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
CA2475764C (en)	2002-03-13	2011-05-31	Janssen Pharmaceutica N.V.	New inhibitors of histone deacetylase
PL214279B1 (pl)	2002-03-13	2013-07-31	Janssen Pharmaceutica Nv	Pochodna sulfonyloaminowa, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania
KR20040090978A (ko) *	2002-03-13	2004-10-27	얀센 파마슈티카 엔.브이.	히스톤 디아세틸라제의 신규한 저해제로서의 설포닐-유도체
NZ534831A (en)	2002-03-13	2007-01-26	Janssen Pharmaceutica Nv	Carbonylamino-derivatives having histone deacetylase (HDAC) inhibiting enzymatic activity
EA007270B1 (ru) *	2002-03-13	2006-08-25	Янссен Фармацевтика Н.В.	Пиперазинил-, пиперидинил- и морфолинилпроизводные как новые ингибиторы гистондеацетилазы
TWI319387B (en)	2002-04-05	2010-01-11	Astrazeneca Ab	Benzamide derivatives
CA2495354A1 (en) *	2002-08-20	2004-03-04	Yamanouchi Pharmaceutical Co., Ltd.	An agent for inhibiting articular cartilage extracellular matrix degradation
AU2003270199A1 (en) *	2002-09-13	2004-04-30	Glaxo Group Limited	Urea compounds active as vanilloid receptor antagonists for the treatment of pain
US20040127571A1 (en) *	2002-09-19	2004-07-01	University Of South Florida	Method of Treating Leukemia with a Combination of Suberoylanilide Hydromaxic Acid and Imatinib Mesylate
WO2004052292A2 (en) *	2002-12-06	2004-06-24	University Of South Florida	Histone deacetylase inhibitor enhancement of trail-induced apoptosis
KR101120414B1 (ko)	2003-04-24	2012-04-12	인사이트 코포레이션	메탈로프로테아제의 억제제로서의 아자 스피로 알칸 유도체
AU2004261250B2 (en)	2003-07-29	2009-02-26	Xenon Pharmaceuticals Inc.	Pyridyl derivatives and their use as therapeutic agents
KR20060037409A (ko)	2003-07-30	2006-05-03	제논 파마슈티칼스 인크.	피페라진 유도체 및 그의 치료제로서의 용도
US7754711B2 (en)	2003-07-30	2010-07-13	Xenon Pharmaceuticals Inc.	Pyridazine derivatives and their use as therapeutic agents
DK1648874T3 (da)	2003-07-30	2012-01-23	Xenon Pharmaceuticals Inc	Piperazinderivater samt deres anvendelse som terapeutisk aktive stoffer
CA2533897A1 (en)	2003-07-30	2005-02-10	Xenon Pharmaceuticals Inc.	Pyridazine derivatives and their use as therapeutic agents
EP2316825A1 (de)	2003-07-30	2011-05-04	Xenon Pharmaceuticals Inc.	Pyridyl Derivate und deren Verwendung als therapeutische Wirkstoffe
AU2004276337B2 (en)	2003-09-24	2009-11-12	Methylgene Inc.	Inhibitors of histone deacetylase
US7253204B2 (en)	2004-03-26	2007-08-07	Methylgene Inc.	Inhibitors of histone deacetylase
KR20070044803A (ko) *	2004-04-09	2007-04-30	뉴로메드 파머큐티칼즈 리미티드	칼슘 채널 차단제로서 디아릴아민 유도체
EP1750712A2 (de) *	2004-05-19	2007-02-14	Solvay Pharmaceuticals GmbH	N-sulfamoyl-n'-phenylpiperazin enthaltendes arzneimittel zur vorbeugung oder behandlung von obesitas und damit zusammenhängenden zuständen
GB0412072D0 (en) *	2004-05-28	2004-06-30	Syngenta Participations Ag	Chemical compounds
EP1758881A1 (de)	2004-06-14	2007-03-07	F.Hoffmann-La Roche Ag	Hydroxamische thiophensäurederivate und deren verwendung als hdac-hemmer
CA2566525A1 (en)	2004-06-14	2005-12-22	F. Hoffmann-La Roche Ag	Thiophene derivatives, their manufacture and use as pharmaceutical agents
PL1781639T3 (pl)	2004-07-28	2012-07-31	Janssen Pharmaceutica Nv	Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej
ME01058B (me) *	2004-07-28	2012-10-20	Janssen Pharmaceutica Nv	Supstituisani derivati propenil piperazina kao novi inhibitori histonske deacetilaze
CN1993356B (zh) *	2004-07-28	2010-10-27	詹森药业有限公司	作为组蛋白脱乙酰基酶新颖抑制剂的取代丙烯基哌嗪衍生物
AU2005272389B2 (en)	2004-08-11	2011-08-04	Kyorin Pharmaceutical Co., Ltd.	Novel cyclic aminobenzoic acid derivative
JP4958787B2 (ja)	2004-09-20	2012-06-20	ゼノン・ファーマシューティカルズ・インコーポレイテッド	ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体
TW200624427A (en)	2004-09-20	2006-07-16	Xenon Pharmaceuticals Inc	Heterocyclic derivatives and their use as therapeutic agents
CA2580787A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
AR051093A1 (es)	2004-09-20	2006-12-20	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
TW200626138A (en)	2004-09-20	2006-08-01	Xenon Pharmaceuticals Inc	Heterocyclic derivatives and their use as therapeutic agents
US7829712B2 (en)	2004-09-20	2010-11-09	Xenon Pharmaceuticals Inc.	Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
BRPI0515478A (pt)	2004-09-20	2008-07-22	Xenon Pharmaceuticals Inc	derivados heterocìclicos e seu uso como mediadores de estearoil-coa-desaturase
EP1807085B1 (de)	2004-09-20	2013-08-21	Xenon Pharmaceuticals Inc.	Heterozyklische Derivate und ihre Verwendung als Stearoyl-Coa-Desaturase-Inhibitoren
GB0421908D0 (en)	2004-10-01	2004-11-03	Angeletti P Ist Richerche Bio	New uses
US7855205B2 (en) *	2004-10-29	2010-12-21	Janssen Pharmaceutica Nv	Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
EP1844778A4 (de) *	2005-02-02	2010-11-03	Kowa Co	Mittel zur prävention/therapie von krankheiten, die durch keratinozytenwachstum hervorgerufen werden
EP2522397A1 (de)	2005-02-03	2012-11-14	TopoTarget UK Limited	Kombinationstherapien mit HDAC-Hemmern
US7772245B2 (en)	2005-02-14	2010-08-10	Miikana Therapeutics, Inc.	Inhibitors of histone deacetylase
US7566718B2 (en) *	2005-02-16	2009-07-28	Schering Corporation	Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
RU2007134259A (ru) *	2005-02-16	2009-03-27	Шеринг Корпорейшн (US)	Гетероциклические замещенные пиперазины, обладающие антагонистическим действием к cxcr3
KR20150008926A (ko) *	2005-03-11	2015-01-23	더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트	암 세포를 표피 성장 인자 억제제에 대해 감작화시키는 히스톤 데아세틸라제 억제제
AU2006240258A1 (en)	2005-04-20	2006-11-02	Merck Sharp & Dohme Corp.	Benzothiophene derivatives
CN101163690A (zh)	2005-04-20	2008-04-16	默克公司	苯并噻吩异羟肟酸衍生物
US7872024B2 (en)	2005-04-20	2011-01-18	Merck Sharp & Dohme Corp.	Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions
GB0509225D0 (en)	2005-05-05	2005-06-15	Chroma Therapeutics Ltd	Inhibitors of enzymatic activity
GB0509223D0 (en)	2005-05-05	2005-06-15	Chroma Therapeutics Ltd	Enzyme inhibitors
EA018982B1 (ru)	2005-05-13	2013-12-30	Топотаргет Юкей Лимитед	Фармацевтические составы, содержащие ингибиторы деацетилазы гистонов
CA2605272C (en)	2005-05-18	2013-12-10	Janssen Pharmaceutica N.V.	Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
GB0510204D0 (en) *	2005-05-19	2005-06-22	Chroma Therapeutics Ltd	Enzyme inhibitors
JP2009513563A (ja)	2005-06-03	2009-04-02	ゼノン・ファーマシューティカルズ・インコーポレイテッド	ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
EP1902051A1 (de) *	2005-06-09	2008-03-26	Merck Frosst Canada Ltd.	Azacyclohexanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
CA2608929C (en) *	2005-06-23	2014-01-28	Janssen Pharmaceutica N.V.	Imidazolinone and hydantoine derivatives as novel inhibitors of histone deacetylase
US8158825B2 (en)	2005-06-24	2012-04-17	Merck Sharp & Dohme Corp.	Modified malonate derivatives
BRPI0613429A2 (pt)	2005-07-14	2009-02-10	Takeda San Diego Inc	inibidores de histona desacetilase
JP2009501733A (ja) *	2005-07-20	2009-01-22	メルクフロストカナダリミテツド	ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのヘテロ芳香族化合物
EP2258357A3 (de)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
EP2275095A3 (de)	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenese durch modulation des Muscarinrezeptors
US20070088043A1 (en) *	2005-10-18	2007-04-19	Orchid Research Laboratories Limited.	Novel HDAC inhibitors
JP2009512711A (ja)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Ｐｄｅ阻害による神経新生の調節
WO2007048767A1 (en)	2005-10-27	2007-05-03	Janssen Pharmaceutica N.V.	Squaric acid derivatives as inhibitors of histone deacetylase
CA2625210A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
KR100696139B1 (ko) *	2005-11-01	2007-03-20	한국화학연구원	히스톤 디아세틸라제 저해활성을 갖는 알킬카바모일나프탈렌일옥시 옥테노일 하이드록시아마이드 유도체 및그의 제조방법
EP2361619A1 (de)	2005-11-10	2011-08-31	TopoTarget UK Limited	Histone Deacetylase (hdac) Inhibitoren (pxd-101) zur Behandlung von hämatologischen Krebserkrankungen
AR057579A1 (es)	2005-11-23	2007-12-05	Merck & Co Inc	Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
US7834025B2 (en)	2006-01-19	2010-11-16	Janssen Pharmaceutica N.V.	Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
RS51191B (sr)	2006-01-19	2010-10-31	Janssen Pharmaceutica N.V.	Derivati aminofenila kao novi inhibitori histon deacetilaze
US8101616B2 (en)	2006-01-19	2012-01-24	Janssen Pharmaceutica N.V.	Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
DK1979328T3 (da) *	2006-01-19	2013-03-25	Janssen Pharmaceutica Nv	Pyridin- og pyrimidinderivater i deres egenskab af histondeacetylasehæmmere
EP1981871B1 (de)	2006-01-19	2011-12-28	Janssen Pharmaceutica N.V.	Heterocyclylalkylderivate als neue inhibitoren von histondeacetylase
US8114876B2 (en) *	2006-01-19	2012-02-14	Janssen Pharmaceutica N.V.	Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US20070202186A1 (en)	2006-02-22	2007-08-30	Iscience Interventional Corporation	Apparatus and formulations for suprachoroidal drug delivery
EP1991226B1 (de)	2006-02-28	2013-03-20	Merck Sharp & Dohme Corp.	Histondeacetylase-hemmer
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
GB0605573D0 (en) *	2006-03-21	2006-04-26	Angeletti P Ist Richerche Bio	Therapeutic Compounds
JP5554988B2 (ja)	2006-04-07	2014-07-23	メチルジーンインコーポレイテッド	ヒストンデアセチラーゼの阻害剤
EP2013196B1 (de)	2006-04-26	2015-09-16	Merck Sharp & Dohme Corp.	Disubstituierte anilinverbindungen
EP2021000A2 (de)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenese mittels angiotensin-modulation
AU2007249435A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 HT receptor mediated neurogenesis
JP2009537529A (ja)	2006-05-18	2009-10-29	メルクエンドカムパニーインコーポレーテッド	アリール縮合スピロ環化合物
EP2049124A4 (de)	2006-07-20	2010-02-10	Merck & Co Inc	Phosphorderivate als histondeacetylasehemmer
AU2007292848A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
GB0619753D0 (en)	2006-10-06	2006-11-15	Chroma Therapeutics Ltd	Enzyme inhibitors
ES2357340T3 (es)	2006-10-18	2011-04-25	Pfizer Products Inc.	Compuestos de biaril éter urea.
ES2509342T3 (es)	2006-10-30	2014-10-17	Chroma Therapeutics Limited	Hidroxamatos como inhibidores de histona desacetilasa
US20080242648A1 (en) *	2006-11-10	2008-10-02	Syndax Pharmaceuticals, Inc., A California Corporation	COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
US8030344B2 (en)	2007-03-13	2011-10-04	Methylgene Inc.	Inhibitors of histone deacetylase
AR066146A1 (es)	2007-04-27	2009-07-29	Shionogi & Co	Antagonistas de trpvi y usos de los mismos
US7737175B2 (en)	2007-06-01	2010-06-15	Duke University	Methods and compositions for regulating HDAC4 activity
CA2726734C (en)	2007-06-06	2014-10-07	University Of Maryland, Baltimore	Hdac inhibitor ms-275 and aromatase inhibitors for the treatment of cancer
WO2008148840A1 (en)	2007-06-08	2008-12-11	Janssen Pharmaceutica N.V.	Piperidine/piperazine derivatives
JO2972B1 (en)	2007-06-08	2016-03-15	جانسين فارماسوتيكا ان. في	Piperidine / piperazine derivatives
RU2470017C2 (ru)	2007-06-08	2012-12-20	Янссен Фармацевтика Н.В.	Производные пиперидина/пиперазина
WO2008148851A1 (en)	2007-06-08	2008-12-11	Janssen Pharmaceutica N.V.	Piperidine/piperazine derivatives
CN101808518A (zh)	2007-06-27	2010-08-18	默沙东公司	作为组蛋白脱乙酰酶抑制剂的吡啶基和嘧啶基衍生物
WO2009002495A1 (en)	2007-06-27	2008-12-31	Merck & Co., Inc.	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20100267779A1 (en) *	2007-07-23	2010-10-21	Syndax Pharmaceuticals, Inc.	Novel Compounds and Methods of Using Them
US20100298270A1 (en) *	2007-07-23	2010-11-25	Syndax Pharmaceuticals, Inc.	Novel Compounds and Methods of Using Them
NZ583495A (en)	2007-09-20	2011-11-25	Irm Llc	Compounds and compositions as modulators of gpr119 activity
EP2203421B1 (de)	2007-09-25	2014-05-07	TopoTarget UK Limited	Verfahren zur synthese bestimmter n-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamiden verbindungen
US20090149511A1 (en) *	2007-10-30	2009-06-11	Syndax Pharmaceuticals, Inc.	Administration of an Inhibitor of HDAC and an mTOR Inhibitor
US20090131367A1 (en) *	2007-11-19	2009-05-21	The Regents Of The University Of Colorado	Combinations of HDAC Inhibitors and Proteasome Inhibitors
WO2009118370A1 (en)	2008-03-27	2009-10-01	Janssen Pharmaceutica Nv	Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
WO2009126662A1 (en) *	2008-04-08	2009-10-15	Syndax Pharmaceuticals, Inc.	Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
US9107946B2 (en)	2008-06-05	2015-08-18	Janssen Pharmaceutica Nv	Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
NZ589532A (en) *	2008-06-12	2012-02-24	Janssen Pharmaceutica Nv	Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor
US8853202B2 (en)	2008-11-04	2014-10-07	Chemocentryx, Inc.	Modulators of CXCR7
JP5785089B2 (ja)	2008-11-04	2015-09-24	ケモセントリックス，インコーポレイティド	Ｃｘｃｒ７の調節因子
WO2010080996A1 (en)	2009-01-08	2010-07-15	Curis, Inc.	Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
JP5597649B2 (ja)	2009-01-28	2014-10-01	カルスセラピューティクスリミテッド	スクリプタイドアイソスター（ｓｃｒｉｐｔａｉｄｉｓｏｓｔｅｒｅｓ）およびその治療における使用
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
GB0903480D0 (en)	2009-02-27	2009-04-08	Chroma Therapeutics Ltd	Enzyme Inhibitors
EP2417123A2 (de)	2009-04-06	2012-02-15	Agios Pharmaceuticals, Inc.	Therapeutische zusammensetzungen und damit in zusammenhang stehende anwendungsverfahren
EP3708169A1 (de) *	2009-06-29	2020-09-16	Agios Pharmaceuticals, Inc.	2,3-dihydrobenzo[b][1,4]dioxin-6-sulfonamid-derivate mit antikrebswirkung
US8609672B2 (en)	2010-08-27	2013-12-17	University Of The Pacific	Piperazinylpyrimidine analogues as protein kinase inhibitors
BR112013009205A2 (pt)	2010-10-15	2016-07-26	Iscience Interventional Corp	dispositivo para colocação na esclera de um olho, método para acessar o espaço supracoroidal de um olho, para acessar o espaço subretinal de um olho e para colocar um orifício dentro de um trato escleral em um olho.
ES2568260T3 (es) *	2010-11-16	2016-04-28	Acetylon Pharmaceuticals, Inc.	Compuestos de pirimidin hidroxi amida como inhibidores de proteína desacetilasa y métodos de uso de los mismos
WO2012071369A2 (en)	2010-11-24	2012-05-31	The Trustees Of Columbia University In The City Of New York	A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
WO2012083246A1 (en)	2010-12-17	2012-06-21	Agios Pharmaceuticals, Inc.	Novel n- (4- (azetidine - 1 - carbonyl) phenyl) - (hetero - ) arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
CA2822432C (en)	2010-12-21	2019-09-24	Agios Pharmaceuticals, Inc.	Bicyclic pkm2 activators
TWI549947B (zh)	2010-12-29	2016-09-21	阿吉歐斯製藥公司	治療化合物及組成物
US8404738B2 (en) *	2011-01-21	2013-03-26	Hoffmann-La Roche Inc.	4-amino-N-hydroxy-benzamides for the treatment of cancer
MX2013010329A (es)	2011-03-09	2014-03-12	Sverker Jern	Compuestos y metodos para mejorarfibrinolisis endogena deteriorada usando inhibidores de histona deacetilasa.
JP6242331B2 (ja)	2011-04-01	2017-12-06	キュリス，インコーポレイテッド	亜鉛結合部分を有するホスホイノシチド３−キナーゼインヒビター
ME03074B (de)	2011-05-03	2019-01-20	Agios Pharmaceuticals Inc	Pyruvatkinaseaktivatoren zur verwendung in der therapie
CN102807526B (zh) *	2011-06-21	2015-12-02	寿光富康制药有限公司	组蛋白去乙酰化酶抑制剂ZYJ-D08a及其差向异构体的制备方法与应用
UA113288C2 (xx)	2011-06-22	2017-01-10		Trpv1 антагоністи, що містять дигідроксизамісник, і їх застосування
FR2976943B1 (fr) *	2011-06-23	2013-07-12	Metabolys	Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
US20150087687A1 (en)	2012-03-23	2015-03-26	Dennis Brown	Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
WO2013166037A1 (en)	2012-05-01	2013-11-07	The Trustees Of Columbia University In The City Of New York	Non-retinoid antagonists for treatment of eye disorders
US20150141470A1 (en)	2012-05-08	2015-05-21	The Broad Institute, Inc.	Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
JP6329958B2 (ja)	2012-11-07	2018-05-23	カルスセラピューティクスリミテッド	新規ヒストンデアセチラーゼインヒビターおよび治療におけるその使用
SG11201504212WA (en)	2012-11-29	2015-06-29	Chemocentryx Inc	Cxcr7 antagonists
CN111557432B (zh)	2013-02-08	2023-08-04	通用磨坊公司	低钠食品
WO2014152018A1 (en)	2013-03-14	2014-09-25	The Trustees Of Columbia University In The City Of New York	Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en)	2013-03-14	2018-04-10	The Trustess Of Columbia University In The City Of New York	N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en)	2013-03-14	2018-04-17	The Trustees Of Columbia University In The City Of New York	Octahydropyrrolopyrroles their preparation and use
WO2014152013A1 (en)	2013-03-14	2014-09-25	The Trustees Of Columbia University In The City Of New York	4-phenylpiperidines, their preparation and use
EA032039B1 (ru)	2013-05-03	2019-03-29	Клиасайд Байомедикал, Инк.	Устройство для проведения глазной инъекции
SI2994465T1 (sl)	2013-05-10	2018-10-30	Karus Therapeutics Limited	Novi inhibitorji histon deacetilaze
EP3003454B1 (de)	2013-06-03	2020-01-08	Clearside Biomedical, Inc.	Vorrichtung zur wirkstofffreisetzung mit mehreren reservoirs
CN104337812B (zh)	2013-07-29	2018-09-14	广东东阳光药业有限公司	取代的杂芳基化合物及其使用方法和用途
ES2929576T3 (es)	2013-10-08	2022-11-30	Acetylon Pharmaceuticals Inc	Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama
WO2015054474A1 (en) *	2013-10-10	2015-04-16	Acetylon Pharmaceuticals, Inc.	Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
US10660890B2 (en)	2013-10-24	2020-05-26	National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr)	Treatment of polycystic diseases with an HDAC6 inhibitor
CR20160308A (es)	2013-12-03	2016-11-08	Acetylon Pharmaceuticals Inc	Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
WO2015090235A1 (en)	2013-12-20	2015-06-25	Sunshine Lake Pharma Co., Ltd.	Substituted piperazine compounds and methods of use thereof
US9464073B2 (en)	2014-02-26	2016-10-11	Acetylon Pharmaceuticals, Inc.	Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
ES2694053T3 (es) *	2014-03-12	2018-12-17	Chong Kun Dang Pharmaceutical Corp.	Compuestos novedosos como inhibidores de histona desacetilasa 6 y composiciones farmacéuticas que comprenden los mismos
CA2947174C (en)	2014-04-30	2023-02-28	The Trustees Of Columbia University In The City Of New York	Substituted 4-phenylpiperidines, their preparaiton and use
CN107205988A (zh)	2014-07-07	2017-09-26	埃斯泰隆制药公司	利用组蛋白脱乙酰酶抑制剂治疗白血病
US10722147B2 (en)	2014-08-13	2020-07-28	Nightbalance B.V.	Activation by temperature sensor
GB201419264D0 (en)	2014-10-29	2014-12-10	Karus Therapeutics Ltd	Compounds
GB201419228D0 (en)	2014-10-29	2014-12-10	Karus Therapeutics Ltd	Compounds
AR102537A1 (es) *	2014-11-05	2017-03-08	Flexus Biosciences Inc	Agentes inmunomoduladores
JP2017537164A (ja)	2014-12-05	2017-12-14	ユニヴァーシティ・オブ・モデナ・アンド・レッジョ・エミリア	リンパ腫の治療に使用されるヒストン脱アセチル化酵素阻害剤とベンダムスチンとの組み合わせ
MX2017007623A (es) *	2014-12-12	2018-09-26	Regenacy Pharmaceuticals Llc	Derivados de piperidina como inhibidores de hdac1/2.
TWI698436B (zh)	2014-12-30	2020-07-11	美商佛瑪治療公司	作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr)	2014-12-30	2017-11-07	Forma Therapeutics Inc	Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
WO2016126926A1 (en)	2015-02-05	2016-08-11	Forma Therapeutics, Inc.	Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
WO2016126935A1 (en)	2015-02-05	2016-08-11	Forma Therapeutics, Inc.	Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
JP2018504431A (ja)	2015-02-05	2018-02-15	フォーマセラピューティクス，インコーポレイテッド	ユビキチン特異的プロテアーゼ７阻害物質としてのチエノピリミジノン
US10272084B2 (en)	2015-06-01	2019-04-30	Regenacy Pharmaceuticals, Llc	Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
CA2989111C (en)	2015-06-11	2023-10-03	Agios Pharmaceuticals, Inc.	Methods of using pyruvate kinase activators
AU2016382372B2 (en) *	2015-12-31	2019-09-19	Hitgen Inc.	Sulfonamide derivative and preparation method and use thereof
WO2017184774A1 (en)	2016-04-19	2017-10-26	Acetylon Pharmaceuticals, Inc.	Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia
JP2019514581A (ja)	2016-05-02	2019-06-06	クリアサイドバイオメディカル，インコーポレイテッド	眼の薬物送達のためのシステムおよび方法
EP3496680B1 (de)	2016-08-12	2024-10-02	Clearside Biomedical, Inc.	Vorrichtung zur einstellung der einsatztiefe einer kanüle zur medikamentenabgabe
WO2018204515A1 (en)	2017-05-02	2018-11-08	Georgia Tech Research Corporation	Targeted drug delivery methods using a microneedle
AU2018342089B2 (en)	2017-09-26	2024-07-11	Dana-Farber Cancer Institute, Inc.	Novel USP7 inhibitors for treating multiple myeloma
CN112313236A (zh)	2018-03-30	2021-02-02	拜欧斯瑞克斯公司	噻吩并嘧啶酮化合物
KR20210087438A (ko)	2018-09-11	2021-07-12	쿠리스 인코퍼레이션	아연 결합 모이어티를 가진 포스포이노시티드 3-키나제 저해제를 이용한 병용 요법
CA3113547A1 (en) *	2018-10-22	2020-04-30	Dana-Farber Cancer Institute, Inc.	Usp7 inhibition
JP2022512367A (ja)	2018-12-12	2022-02-03	ケモセントリックス，インコーポレイティド	癌治療のためのｃｘｃｒ７阻害剤
CA3229226A1 (en)	2021-08-18	2023-02-23	Chemocentryx, Inc.	Aryl sulfonyl compounds as ccr6 inhibitors
EP4387609A2 (de)	2021-08-18	2024-06-26	ChemoCentryx, Inc.	Arylsulfonyl(hydroxy)piperidine als ccr6-inhibitoren
WO2023222115A1 (zh) *	2022-05-20	2023-11-23	四川汇宇制药股份有限公司	一种羟基酰胺类衍生物及其应用
CN117263936B (zh) *	2023-11-21	2024-02-23	中国中医科学院医学实验中心	一种咪唑并[1, 2-a]吡啶衍生物及其制备方法和在中枢神经系统渗透性HDAC6抑制药物中的应用

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB901749A (en) *	1957-12-06	1962-07-25	Ciba Ltd	New 2-substituted pyrimidines
US2927924A (en) *	1958-04-03	1960-03-08	Lilly Co Eli	Novel phenethyl-substituted piperazines
NL297170A (de) *	1963-04-04	1900-01-01
US3331845A (en) *	1963-04-04	1967-07-18	American Cyanamid Co	1-substituted-4-substituted amino alkylene piperazines
US3459731A (en) *	1966-12-16	1969-08-05	Corn Products Co	Cyclodextrin polyethers and their production
US3966743A (en) *	1968-07-23	1976-06-29	Boehringer Mannheim G.M.B.H.	Ortho fused cycloalkano-4-quinolone-3-carboxylic acid derivatives
US4049811A (en) *	1968-07-23	1977-09-20	Boehringer Mannheim G.M.B.H.	Compositions using cycloalkano-quinolone derivatives and their method of use
GB1345872A (en)	1970-09-03	1974-02-06	Wyeth John & Brother Ltd	Amino-and acylamino-pyridine and hydropyridine derivatives
JPS5755714B2 (de) *	1972-03-18	1982-11-25
US4186199A (en) *	1978-11-02	1980-01-29	American Hoechst Corporation	Indolo-,1,2-dihydroindolo-, and 1,2,6,7-tetrahydroindolo [1,7-ab][1,5] benzodiazepines
DE2939292A1 (de) *	1979-09-28	1981-04-09	Boehringer Mannheim Gmbh, 6800 Mannheim	N-phenoxyalkylpiperidin-derivate, verfahrenn zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
PH17194A (en) *	1980-03-06	1984-06-19	Otsuka Pharma Co Ltd	Novel carbostyril derivatives,and pharmaceutical composition containing the same
CA1183847A (en)	1981-10-01	1985-03-12	Georges Van Daele	N-(3-hydroxy-4-piperidinyl)benzamide derivatives
JPS6143173A (ja) *	1984-08-06	1986-03-01	Mitsui Petrochem Ind Ltd	新規ピリミジン誘導体およびその製法
JPS6187672A (ja) *	1984-10-08	1986-05-06	Mitsui Petrochem Ind Ltd	新規ピリミジン誘導体
EP0188095A1 (de)	1984-12-13	1986-07-23	East Rock Technology Inc.	Verfahren zur Herstellung einer ringförmigen Vorschaltdrossel und Vorrichtung zur Durchführung dieses Verfahrens
JPS61140568A (ja) *	1984-12-14	1986-06-27	Mitsui Petrochem Ind Ltd	キナゾリン誘導体及びそれを有効成分とする血圧降下剤
CA1307786C (en) *	1984-12-14	1992-09-22	Keiichi Yokoyama	Quinazoline derivatives and antihypertensive preparations containing same as effective components
US4840947A (en) *	1986-10-14	1989-06-20	Hoechst-Roussel Pharmaceuticals, Inc.	Antiinflammatory and analgesic piperidin-4-yl-tetracyclic benzodiazepines and use thereas
JP2744663B2 (ja) *	1988-12-29	1998-04-28	三井化学株式会社	ピリミジン類及びその薬学的に許容される塩類
HU206337B (en) *	1988-12-29	1992-10-28	Mitsui Petrochemical Ind	Process for producing pyrimidine derivatives and pharmaceutical compositions
DK0382185T3 (da) *	1989-02-10	1994-07-04	Otsuka Pharma Co Ltd	Carbostyrilderivater
JP2664238B2 (ja) *	1989-03-01	1997-10-15	日清製粉株式会社	ニコチン酸またはそのエステル誘導体
US5342846A (en) *	1990-12-05	1994-08-30	Synphar Laboratories, Inc.	7-substituted-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid compounds and 7-(substituted triazolyl pyrrolidin-1-yl) 4-oxoquinoline-3-carboxylic acid derivatives useful as antibacterial agents
EP0524146A1 (de) *	1991-07-19	1993-01-20	Ciba-Geigy Ag	Aminosubstituierte Piperazinderivate
TW213903B (de) *	1991-08-16	1993-10-01	Boehringer Ingelheim Kg
DE4228792A1 (de)	1992-08-29	1994-03-03	Hoechst Ag	Pyridylaminopiperidine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und deren Verwendung als Fungizide
US5338738A (en) *	1993-04-19	1994-08-16	Bristol-Myers Squibb Company	Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines
US5459151A (en)	1993-04-30	1995-10-17	American Home Products Corporation	N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents
FR2722788B1 (fr) *	1994-07-20	1996-10-04	Pf Medicament	Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant
US6083903A (en) *	1994-10-28	2000-07-04	Leukosite, Inc.	Boronic ester and acid compounds, synthesis and uses
ES2104509B1 (es)	1995-06-13	1998-07-01	Ferrer Int	Nuevos compuestos derivados de 2-(3,4-disustituido-1-piperazinil)-5-fluoropirimidina.
JPH0959236A (ja) *	1995-08-23	1997-03-04	Dai Ichi Seiyaku Co Ltd	ベンズアミド化合物
NZ322907A (en)	1995-11-23	1998-12-23	Janssen Pharmaceutica Nv	Solid mixtures of cyclodextrins prepared via melt-extrusion
ZA9610745B (en)	1995-12-22	1997-06-24	Warner Lambert Co	4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
US5952349A (en) *	1996-07-10	1999-09-14	Schering Corporation	Muscarinic antagonists for treating memory loss
US5866702A (en)	1996-08-02	1999-02-02	Cv Therapeutics, Incorporation	Purine inhibitors of cyclin dependent kinase 2
EP0827742A1 (de) *	1996-09-04	1998-03-11	Vrije Universiteit Brussel	Verwendung von Histondeacetylasehemmern zur Behandlung von Fibrose oder Zirrhose
SE9604786D0 (sv) *	1996-12-20	1996-12-20	Astra Pharma Inc	New compounds
FR2761960B1 (fr)	1997-04-09	1999-05-28	Pechiney Emballage Flexible Eu	Film a base de polyolefine pour former un emballage par pliage
AUPO721997A0 (en)	1997-06-06	1997-07-03	Queensland Institute Of Medical Research, The	Anticancer compounds
EP0891930A1 (de)	1997-07-17	1999-01-20	Alusuisse Technology & Management AG	Verpackungsfolie
DE19743435A1 (de)	1997-10-01	1999-04-08	Merck Patent Gmbh	Benzamidinderivate
US6750228B1 (en) *	1997-11-14	2004-06-15	Pharmacia Corporation	Aromatic sulfone hydroxamic acid metalloprotease inhibitor
ES2193660T3 (es)	1998-03-27	2003-11-01	Janssen Pharmaceutica Nv	Derivados de pirimidina inhibidores de vih.
EP1080069B1 (de) *	1998-04-20	2003-03-19	Fujisawa Pharmaceutical Co., Ltd.	Anthranilsäurederivate als inhibitoren der c-gmp-phosphodiesterase
JPH11335375A (ja) *	1998-05-20	1999-12-07	Mitsui Chem Inc	ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
RU2216541C2 (ru) *	1998-08-04	2003-11-20	Астразенека Аб	Производные бензамида, способ их получения и фармацевтическая композиция на их основе
GB9823873D0 (en) *	1998-10-30	1998-12-30	Pharmacia & Upjohn Spa	2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
EA004049B1 (ru)	1998-11-10	2003-12-25	Янссен Фармацевтика Н.В.	Пиримидины, ингибирующие репликацию вич
BR9916211A (pt)	1998-12-14	2001-09-11	American Home Prod	Derivados de 3,4-diamino-3-ciclobuteno-1,2-diona que inibem adesão de leucócito mediada por vla-4
US6635657B1 (en) *	1998-12-23	2003-10-21	Eli Lilly And Company	Aromatic amides
CZ27399A3 (cs)	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1075469B1 (de) *	1999-03-03	2004-05-26	Samjin Pharmaceutical Co., Ltd.	Piperazinderivate und verfahren zu ihrer herstellung
EP1041068B1 (de) *	1999-04-01	2004-04-14	Pfizer Products Inc.	Verbindungen zur Behandlung und Vorsorge bei Diabetes
WO2000071515A2 (en)	1999-05-24	2000-11-30	Cor Therapeutics, Inc	INHIBITORS OF FACTOR Xa
US6518283B1 (en) *	1999-05-28	2003-02-11	Celltech R&D Limited	Squaric acid derivatives
AU5108000A (en) *	1999-06-10	2001-01-02	Yamanouchi Pharmaceutical Co., Ltd.	Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
GB9918035D0 (en)	1999-07-30	1999-09-29	Novartis Ag	Organic compounds
DK1218341T3 (da) *	1999-09-01	2005-12-12	Sanofi Aventis Deutschland	Sulfonylcarboxamid-derivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
AU783504C (en) *	1999-11-23	2006-08-03	Methylgene Inc.	Inhibitors of histone deacetylase
CZ20022353A3 (cs)	2000-01-07	2003-02-12	Universitaire Instelling Antwerpen	Deriváty purinu, způsob jejich přípravy a jejich použití
US6608052B2 (en) *	2000-02-16	2003-08-19	Boehringer Ingelheim Pharmaceuticals, Inc.	Compounds useful as anti-inflammatory agents
ATE489360T1 (de) *	2000-03-24	2010-12-15	Methylgene Inc	Inhibitoren der histon-deacetylase
DE10023484A1 (de) *	2000-05-09	2001-11-22	Schering Ag	Anthranylamide und deren Verwendung als Arzneimittel
WO2002000651A2 (en)	2000-06-27	2002-01-03	Bristol-Myers Squibb Pharma Company	Factor xa inhibitors
AU2001280187A1 (en)	2000-08-28	2002-03-13	Toray Industries, Inc.	Cyclic amine derivatives
ES2167276B1 (es) *	2000-10-20	2003-04-01	Esteve Labor Dr	Nuevos derivados de cianoaril (o cianoheteroaril)-carbonil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.
JO2409B1 (en)	2000-11-21	2007-06-17	شركة جانسين فارماسوتيكا ان. في	Second-phenyl carboxy amides are useful as lipid-lowering agents
MXPA03009602A (es) *	2001-04-18	2004-04-02	Euro Celtique Sa	Analogos de nociceptina.
SE0101771D0 (sv) *	2001-05-18	2001-05-18	Astrazeneca Ab	Novel compounds
SE0101769D0 (sv) *	2001-05-18	2001-05-18	Astrazeneca Ab	Novel compounds
US6784173B2 (en) *	2001-06-15	2004-08-31	Hoffmann-La Roche Inc.	Aromatic dicarboxylic acid derivatives
DE10130374A1 (de)	2001-06-23	2003-01-02	Boehringer Ingelheim Pharma	Substituierte N-Acyl-anilinderivate, deren Herstellung und deren Verwendung als Arzneimittel
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
US6897220B2 (en)	2001-09-14	2005-05-24	Methylgene, Inc.	Inhibitors of histone deacetylase
US7129034B2 (en)	2001-10-25	2006-10-31	Cedars-Sinai Medical Center	Differentiation of whole bone marrow
GB0127929D0 (en) *	2001-11-21	2002-01-16	Celltech R&D Ltd	Chemical compounds
GB0229931D0 (en)	2002-12-21	2003-01-29	Astrazeneca Ab	Therapeutic agents
ES2610611T3 (es) *	2002-01-18	2017-04-28	Astellas Pharma Inc.	Derivado de 2-acilaminotiazol o sal del mismo
EP1472216A2 (de)	2002-02-07	2004-11-03	Axys Pharmaceuticals	Neue bicyclische hydroxamsäuren als hemmer der histon deacetylase
AU2003202115A1 (en) *	2002-02-12	2003-09-04	Pfizer Inc.	Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
CA2475764C (en)	2002-03-13	2011-05-31	Janssen Pharmaceutica N.V.	New inhibitors of histone deacetylase
EA007270B1 (ru)	2002-03-13	2006-08-25	Янссен Фармацевтика Н.В.	Пиперазинил-, пиперидинил- и морфолинилпроизводные как новые ингибиторы гистондеацетилазы
EP1485378B1 (de)	2002-03-13	2008-06-18	Janssen Pharmaceutica N.V.	Piperazinyl-, piperidinyl- und morpholinylderivate als neue inhibitoren von histon-deacetylase
PL214279B1 (pl)	2002-03-13	2013-07-31	Janssen Pharmaceutica Nv	Pochodna sulfonyloaminowa, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania
KR20040090978A (ko) *	2002-03-13	2004-10-27	얀센 파마슈티카 엔.브이.	히스톤 디아세틸라제의 신규한 저해제로서의 설포닐-유도체
NZ534831A (en) *	2002-03-13	2007-01-26	Janssen Pharmaceutica Nv	Carbonylamino-derivatives having histone deacetylase (HDAC) inhibiting enzymatic activity
US6897307B2 (en) *	2002-03-28	2005-05-24	Novartis Ag	Process for preparing 2,6-diaminopurine derivatives
MXPA04009490A (es)	2002-04-03	2005-06-08	Topo Target Uk Ltd	Compuesto de acido carbamico que comprenden un enlace de piperazina como inhibidores de histona desacetilasa.
TWI319387B (en)	2002-04-05	2010-01-11	Astrazeneca Ab	Benzamide derivatives
GB0209715D0 (en)	2002-04-27	2002-06-05	Astrazeneca Ab	Chemical compounds
DE10233412A1 (de)	2002-07-23	2004-02-12	4Sc Ag	Neue Verbindungen als Histondeacetylase-Inhibitoren
MXPA05001334A (es)	2002-08-02	2005-09-08	Argenta Discovery Ltd	Acidos tienil-hidroxamicos sustituidos como inhibidores de la desacetilasa de histona.
ITMI20030025A1 (it)	2003-01-10	2004-07-11	Italfarmaco Spa	Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
TW200418806A (en)	2003-01-13	2004-10-01	Fujisawa Pharmaceutical Co	HDAC inhibitor
CA2513246A1 (en)	2003-01-17	2004-08-05	Topotarget Uk Limited	Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors
TW200424174A (en)	2003-02-06	2004-11-16	Hoffmann La Roche	New TP diamide
AU2003900608A0 (en)	2003-02-11	2003-02-27	Fujisawa Pharmaceutical Co., Ltd.	Hdac inhibitor
US7244751B2 (en)	2003-02-14	2007-07-17	Shenzhen Chipscreen Biosciences Ltd.	Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
JP2006520796A (ja)	2003-03-17	2006-09-14	タケダサンディエゴインコーポレイテッド	ヒストンデアセチラーゼインヒビター
TW200424187A (en)	2003-04-04	2004-11-16	Hoffmann La Roche	New oxime derivatives and their use as pharmaceutically active agents
DK1611088T3 (da)	2003-04-07	2009-10-19	Pharmacyclics Inc	Hydroxymater som terapeutiske midler
US7470717B2 (en)	2003-07-30	2008-12-30	Kyowa Hakko Kogyo Co., Ltd.	Indazole derivatives
TWI351963B (en)	2003-09-17	2011-11-11	Yeastern Biotech Co Ltd	Fungal immunomodulatory protein (fip) prepared by
PT1673349E (pt)	2003-09-22	2010-09-28	S Bio Pte Ltd	Derivados benzimidazole: preparação e aplicações farmacêuticas
SI1673349T1 (sl)	2003-09-22	2010-10-29	S Bio Pte Ltd	Derivati benzimidazola: priprava in farmacevtske uporabe
AU2004276337B2 (en)	2003-09-24	2009-11-12	Methylgene Inc.	Inhibitors of histone deacetylase
US20070167499A1 (en)	2003-10-27	2007-07-19	A*Bio Pte Ltd.	Biaryl linked hydroxamates: preparation and pharmaceutical applications
EP1685094A4 (de)	2003-10-27	2007-08-22	S Bio Pte Ltd	Mit acylharnstoff verbundene und mit sulfonylharnstoff verbundene hydroxamate
GB0402496D0 (en)	2004-02-04	2004-03-10	Argenta Discovery Ltd	Novel compounds
US20050197336A1 (en)	2004-03-08	2005-09-08	Miikana Therapeutics Corporation	Inhibitors of histone deacetylase
AU2005225471B2 (en)	2004-03-26	2011-05-12	Methylgene Inc.	Inhibitors of histone deacetylase
ME01058B (me) *	2004-07-28	2012-10-20	Janssen Pharmaceutica Nv	Supstituisani derivati propenil piperazina kao novi inhibitori histonske deacetilaze
PL1781639T3 (pl)	2004-07-28	2012-07-31	Janssen Pharmaceutica Nv	Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej
CN1993356B (zh)	2004-07-28	2010-10-27	詹森药业有限公司	作为组蛋白脱乙酰基酶新颖抑制剂的取代丙烯基哌嗪衍生物
CA2605272C (en) *	2005-05-18	2013-12-10	Janssen Pharmaceutica N.V.	Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
CA2608929C (en)	2005-06-23	2014-01-28	Janssen Pharmaceutica N.V.	Imidazolinone and hydantoine derivatives as novel inhibitors of histone deacetylase
CA2611438C (en)	2005-06-30	2014-01-07	Janssen Pharmaceutica N.V.	Cyclic anilino-pyridinotriazines
WO2007016532A2 (en)	2005-08-02	2007-02-08	Novartis Ag	Mutations and polymorphisms of hdac4
WO2007048767A1 (en)	2005-10-27	2007-05-03	Janssen Pharmaceutica N.V.	Squaric acid derivatives as inhibitors of histone deacetylase
DK1979328T3 (da)	2006-01-19	2013-03-25	Janssen Pharmaceutica Nv	Pyridin- og pyrimidinderivater i deres egenskab af histondeacetylasehæmmere
US7834025B2 (en) *	2006-01-19	2010-11-16	Janssen Pharmaceutica N.V.	Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
EP1981871B1 (de)	2006-01-19	2011-12-28	Janssen Pharmaceutica N.V.	Heterocyclylalkylderivate als neue inhibitoren von histondeacetylase
RS51191B (sr)	2006-01-19	2010-10-31	Janssen Pharmaceutica N.V.	Derivati aminofenila kao novi inhibitori histon deacetilaze
US8114876B2 (en) *	2006-01-19	2012-02-14	Janssen Pharmaceutica N.V.	Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8101616B2 (en) *	2006-01-19	2012-01-24	Janssen Pharmaceutica N.V.	Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
CN101516375B (zh)	2006-09-15	2012-10-03	詹森药业有限公司	类别-i具体组织蛋白脱乙酰基酶抑制剂与蛋白酶体抑制剂的组合
EP2234883B1 (de)	2007-12-14	2017-08-02	Urban Aeronautics Ltd.	Vtol fahrzeug und verfahren zum betrieb
GB0901749D0 (en)	2009-02-03	2009-03-11	Oxford Nanopore Tech Ltd	Adaptor method

2003
- 2003-03-11 CA CA2475764A patent/CA2475764C/en not_active Expired - Fee Related
- 2003-03-11 PL PL370992A patent/PL213783B1/pl unknown
- 2003-03-11 IL IL16400303A patent/IL164003A0/xx unknown
- 2003-03-11 ES ES03708214T patent/ES2322950T3/es not_active Expired - Lifetime
- 2003-03-11 AT AT03708214T patent/ATE425152T1/de not_active IP Right Cessation
- 2003-03-11 JP JP2003574621A patent/JP4644428B2/ja not_active Expired - Fee Related
- 2003-03-11 NZ NZ534834A patent/NZ534834A/en unknown
- 2003-03-11 IL IL16400603A patent/IL164006A0/xx unknown
- 2003-03-11 JP JP2003574203A patent/JP4725944B2/ja not_active Expired - Lifetime
- 2003-03-11 ES ES03711981T patent/ES2347544T3/es not_active Expired - Lifetime
- 2003-03-11 AT AT03711981T patent/ATE473005T1/de not_active IP Right Cessation
- 2003-03-11 WO PCT/EP2003/002514 patent/WO2003076400A1/en active IP Right Grant
- 2003-03-11 EP EP03711981A patent/EP1485099B1/de not_active Expired - Lifetime
- 2003-03-11 AU AU2003212335A patent/AU2003212335B8/en not_active Ceased
- 2003-03-11 BR BR0308081-1A patent/BR0308081A/pt not_active IP Right Cessation
- 2003-03-11 EA EA200401201A patent/EA007272B1/ru not_active IP Right Cessation
- 2003-03-11 AU AU2003218737A patent/AU2003218737B2/en not_active Ceased
- 2003-03-11 IL IL16400503A patent/IL164005A0/xx not_active IP Right Cessation
- 2003-03-11 CN CN038058332A patent/CN1642551B/zh not_active Expired - Lifetime
- 2003-03-11 WO PCT/EP2003/002515 patent/WO2003075929A1/en active IP Right Grant
- 2003-03-11 CA CA2476065A patent/CA2476065C/en not_active Expired - Lifetime
- 2003-03-11 DE DE60326436T patent/DE60326436D1/de not_active Expired - Lifetime
- 2003-03-11 EP EP03711980A patent/EP1485353B1/de not_active Expired - Lifetime
- 2003-03-11 CA CA2476296A patent/CA2476296C/en not_active Expired - Lifetime
- 2003-03-11 PL PL370991A patent/PL212089B1/pl unknown
- 2003-03-11 MX MXPA04008806A patent/MXPA04008806A/es active IP Right Grant
- 2003-03-11 IL IL16400703A patent/IL164007A0/xx active IP Right Grant
- 2003-03-11 KR KR10-2004-7011024A patent/KR20040090979A/ko not_active Application Discontinuation
- 2003-03-11 MX MXPA04008797A patent/MXPA04008797A/es active IP Right Grant
- 2003-03-11 CN CNB038056755A patent/CN100519527C/zh not_active Expired - Fee Related
- 2003-03-11 JP JP2003574647A patent/JP4472353B2/ja not_active Expired - Lifetime
- 2003-03-11 OA OA1200400245A patent/OA12791A/en unknown
- 2003-03-11 BR BR0307624-5A patent/BR0307624A/pt not_active IP Right Cessation
- 2003-03-11 DE DE60326549T patent/DE60326549D1/de not_active Expired - Lifetime
- 2003-03-11 DE DE60333260T patent/DE60333260D1/de not_active Expired - Lifetime
- 2003-03-11 EA EA200401199A patent/EA008245B1/ru not_active IP Right Cessation
- 2003-03-11 EP EP03708216A patent/EP1485370B1/de not_active Expired - Lifetime
- 2003-03-11 ES ES03711980T patent/ES2371632T3/es not_active Expired - Lifetime
- 2003-03-11 ES ES03708216T patent/ES2322252T3/es not_active Expired - Lifetime
- 2003-03-11 US US10/506,998 patent/US7816363B2/en not_active Expired - Fee Related
- 2003-03-11 DK DK03711980.7T patent/DK1485353T3/da active
- 2003-03-11 AT AT03711980T patent/ATE521592T1/de not_active IP Right Cessation
- 2003-03-11 KR KR10-2004-7011509A patent/KR20040090985A/ko not_active Application Discontinuation
- 2003-03-11 AT AT03708216T patent/ATE424395T1/de not_active IP Right Cessation
- 2003-03-11 NZ NZ534832A patent/NZ534832A/en unknown
- 2003-03-11 WO PCT/EP2003/002513 patent/WO2003076430A1/en active Application Filing
- 2003-03-11 EP EP03708214A patent/EP1485364B1/de not_active Expired - Lifetime
- 2003-03-11 JP JP2003574640A patent/JP4836405B2/ja not_active Expired - Lifetime
- 2003-03-11 WO PCT/EP2003/002511 patent/WO2003076421A1/en active Application Filing
- 2003-03-11 US US10/507,785 patent/US7615553B2/en active Active
- 2003-03-11 CA CA2476583A patent/CA2476583C/en not_active Expired - Lifetime
- 2003-03-11 US US10/507,784 patent/US7541369B2/en not_active Expired - Lifetime
- 2003-03-11 AU AU2003212337A patent/AU2003212337B2/en not_active Ceased
- 2003-03-11 IL IL16400403A patent/IL164004A0/xx unknown
- 2003-03-11 AU AU2003218736A patent/AU2003218736B2/en not_active Ceased
- 2003-03-11 US US10/507,271 patent/US7501417B2/en not_active Expired - Lifetime
- 2003-03-11 OA OA1200400244A patent/OA12790A/en unknown
- 2003-03-12 AR ARP030100854A patent/AR039566A1/es not_active Application Discontinuation
- 2003-03-12 TW TW092105284A patent/TW200400822A/zh unknown
- 2003-11-03 UA UA20040907276A patent/UA77263C2/uk unknown
- 2003-11-03 UA UA20041008337A patent/UA78033C2/uk unknown
- 2003-11-03 UA UA20041008334A patent/UA78031C2/uk unknown
- 2003-11-03 UA UA20041008336A patent/UA78032C2/uk unknown
2004
- 2004-09-03 HR HR20040799A patent/HRP20040799A2/hr not_active Application Discontinuation
- 2004-09-03 HR HR20040803A patent/HRP20040803A2/hr not_active Application Discontinuation
- 2004-09-09 IL IL164007A patent/IL164007A/en not_active IP Right Cessation
- 2004-09-09 ZA ZA200407235A patent/ZA200407235B/en unknown
- 2004-09-09 ZA ZA200407234A patent/ZA200407234B/en unknown
- 2004-09-09 ZA ZA200407232A patent/ZA200407232B/en unknown
- 2004-09-09 ZA ZA200407236A patent/ZA200407236B/en unknown
- 2004-09-09 ZA ZA200407233A patent/ZA200407233B/en unknown
- 2004-09-09 ZA ZA200407237A patent/ZA200407237B/en unknown
- 2004-09-09 IL IL164006A patent/IL164006A/en not_active IP Right Cessation
- 2004-09-28 NO NO20044113A patent/NO20044113L/no not_active Application Discontinuation
- 2004-10-01 NO NO20044194A patent/NO20044194L/no not_active Application Discontinuation
2005
- 2005-11-18 HK HK05110453.4A patent/HK1078473A1/xx not_active IP Right Cessation
2009
- 2009-01-27 US US12/360,139 patent/US8114999B2/en not_active Expired - Fee Related
- 2009-02-18 US US12/372,801 patent/US8268833B2/en not_active Expired - Fee Related
- 2009-02-18 US US12/372,785 patent/US8343988B2/en not_active Expired - Fee Related
- 2009-04-24 US US12/429,838 patent/US20090227558A1/en not_active Abandoned
- 2009-09-16 US US12/560,657 patent/US8455498B2/en not_active Expired - Lifetime
2011
- 2011-12-30 US US13/341,316 patent/US20120108603A1/en not_active Abandoned
2012
- 2012-05-15 US US13/471,579 patent/US8524711B2/en not_active Expired - Lifetime
2013
- 2013-05-06 US US13/887,681 patent/US8697717B2/en not_active Expired - Lifetime
- 2013-07-22 US US13/947,308 patent/US8916554B2/en not_active Expired - Lifetime
2014
- 2014-02-21 US US14/186,343 patent/US9150560B2/en not_active Expired - Fee Related
- 2014-11-11 US US14/538,317 patent/US9533979B2/en not_active Expired - Lifetime
2015
- 2015-08-21 US US14/832,101 patent/US9556161B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
IL164006A0 (en)	2005-12-18
EA007272B1 (ru)	2006-08-25
PL370991A1 (en)	2005-06-13
EP1485099A1 (de)	2004-12-15
CA2476583C (en)	2011-07-05
ZA200407236B (en)	2005-10-06
EP1485370B1 (de)	2009-03-04
PL370992A1 (en)	2005-06-13
US9556161B2 (en)	2017-01-31
IL164003A0 (en)	2005-12-18
ZA200407235B (en)	2005-10-04
AU2003218736B2 (en)	2009-01-08
KR20040090985A (ko)	2004-10-27
EA200401199A1 (ru)	2005-02-24
CA2476065C (en)	2012-07-24
JP4472353B2 (ja)	2010-06-02
ATE473005T1 (de)	2010-07-15
NO20044113L (no)	2004-09-28
MXPA04008806A (es)	2004-11-26
EA200401201A1 (ru)	2005-02-24
US7541369B2 (en)	2009-06-02
JP2005526067A (ja)	2005-09-02
BR0308081A (pt)	2004-12-21
AU2003218737A1 (en)	2003-09-22
US8268833B2 (en)	2012-09-18
IL164005A0 (en)	2005-12-18
IL164007A (en)	2011-03-31
BR0307624A (pt)	2005-01-11
IL164006A (en)	2010-11-30
MXPA04008797A (es)	2004-11-26
ATE424395T1 (de)	2009-03-15
CA2475764C (en)	2011-05-31
US8455498B2 (en)	2013-06-04
WO2003076421A1 (en)	2003-09-18
US8697717B2 (en)	2014-04-15
UA77263C2 (en)	2006-11-15
EP1485370A1 (de)	2004-12-15
JP4644428B2 (ja)	2011-03-02
US20130245034A1 (en)	2013-09-19
DE60326436D1 (en)	2009-04-16
CN100519527C (zh)	2009-07-29
NZ534834A (en)	2005-07-29
US20090227558A1 (en)	2009-09-10
US20100010004A1 (en)	2010-01-14
UA78033C2 (en)	2007-02-15
HRP20040803A2 (en)	2005-02-28
TW200400822A (en)	2004-01-16
US7501417B2 (en)	2009-03-10
NZ534832A (en)	2005-09-30
EA008245B1 (ru)	2007-04-27
US20150353549A1 (en)	2015-12-10
US20090170881A1 (en)	2009-07-02
KR20040090979A (ko)	2004-10-27
ZA200407232B (en)	2005-10-06
PL212089B1 (pl)	2012-08-31
PL213783B1 (pl)	2013-05-31
JP4836405B2 (ja)	2011-12-14
IL164007A0 (en)	2005-12-18
CA2476296C (en)	2011-02-22
CN1642551B (zh)	2011-09-14
ATE521592T1 (de)	2011-09-15
AR039566A1 (es)	2005-02-23
JP2005525379A (ja)	2005-08-25
US8114999B2 (en)	2012-02-14
UA78032C2 (en)	2007-02-15
ES2322950T3 (es)	2009-07-02
CA2476065A1 (en)	2003-09-18
ATE425152T1 (de)	2009-03-15
UA78031C2 (en)	2007-02-15
EP1485364A1 (de)	2004-12-15
WO2003076430A1 (en)	2003-09-18
CA2476296A1 (en)	2003-09-18
DK1485353T3 (da)	2011-11-28
US9533979B2 (en)	2017-01-03
EP1485353A1 (de)	2004-12-15
CN1639125A (zh)	2005-07-13
JP2005525381A (ja)	2005-08-25
EP1485099B1 (de)	2010-07-07
AU2003218736A1 (en)	2003-09-22
AU2003218737B2 (en)	2008-04-10
US20050119250A1 (en)	2005-06-02
AU2003212335B8 (en)	2009-04-23
AU2003212337A1 (en)	2003-09-22
EP1485353B1 (de)	2011-08-24
US20050222414A1 (en)	2005-10-06
JP4725944B2 (ja)	2011-07-13
ZA200407233B (en)	2005-10-06
CA2476583A1 (en)	2003-09-18
US8343988B2 (en)	2013-01-01
ES2322252T3 (es)	2009-06-18
US7816363B2 (en)	2010-10-19
CA2475764A1 (en)	2003-09-18
US20120108603A1 (en)	2012-05-03
WO2003075929A1 (en)	2003-09-18
AU2003212335A1 (en)	2003-09-22
US8916554B2 (en)	2014-12-23
JP2005523907A (ja)	2005-08-11
NO20044194L (no)	2004-10-01
DE60326549D1 (en)	2009-04-23
US7615553B2 (en)	2009-11-10
OA12791A (en)	2006-07-10
OA12790A (en)	2006-07-10
US20050107384A1 (en)	2005-05-19
ES2371632T3 (es)	2012-01-05
ZA200407234B (en)	2005-10-06
US20100048588A1 (en)	2010-02-25
HK1078473A1 (en)	2006-03-17
US9150560B2 (en)	2015-10-06
CN1642551A (zh)	2005-07-20
ZA200407237B (en)	2005-09-28
US8524711B2 (en)	2013-09-03
EP1485364B1 (de)	2009-03-11
AU2003212335B2 (en)	2008-11-27
US20130303506A1 (en)	2013-11-14
US20050096468A1 (en)	2005-05-05
IL164004A0 (en)	2005-12-18
WO2003076400A1 (en)	2003-09-18
HRP20040799A2 (en)	2005-04-30
US20150065478A1 (en)	2015-03-05
US20120252790A1 (en)	2012-10-04
US20090170836A1 (en)	2009-07-02
AU2003212337B2 (en)	2009-06-11
US20140171439A1 (en)	2014-06-19
ES2347544T3 (es)	2010-11-02

Publication	Publication Date	Title
DE60333260D1 (en)	2010-08-19	Histone-deacetylase-inhibitoren
DE60325365D1 (en)	2009-01-29	Clip-operationsgerät
DE60311980D1 (en)	2007-04-05	Histondeacetylase-hemmer
DE50312422D1 (en)	2010-04-01	Aryloxime
DE60315313D1 (en)	2007-09-13	Polytrimethylenetherester
DE60319515D1 (en)	2008-04-17	Delta-sigma-modulator
DE60317770D1 (en)	2008-01-10	Astaxanthinester
AU2003249738A8 (en)	2004-01-23	Ostoscope
AU2003297193A8 (en)	2004-07-09	Meta-web
DE60303791D1 (en)	2006-04-27	Aza-arylpiperazine
DE50309217D1 (en)	2008-04-03	Benzimidazolderivate
AU2003252028A8 (en)	2004-02-09	Heterodiamondoids
DE60324012D1 (en)	2008-11-20	Elektrophotographischer photorezeptor
AU2003279495A8 (en)	2004-05-13	Alert-modeling
DE50308027D1 (en)	2007-10-04	Cyclohexyl-harnstoff-derivate
DE50303619D1 (en)	2006-07-06	Reibschweissvorrichtung
DE50313444D1 (en)	2011-03-10	Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
DE60319980D1 (en)	2008-05-08	Xanthin-phosphodiesterase-v-hemmer polymorphe
DE50307787D1 (en)	2007-09-06	Isophthalsäurederivate
DE50312412D1 (en)	2010-03-25	4-hydroxymethyl-1-aryl-cyclohexylamin-derivative
DE60224584D1 (en)	2008-02-21	Rotationsdämpfer
DE60310887D1 (en)	2007-02-15	Epilatorstreifen
AU2003264900A8 (en)	2004-04-08	Cast-cutter
AU2002367810A8 (en)	2003-11-10	Bis-transition-metal-chelate-probes
DE60325705D1 (en)	2009-02-26	Tc-thermistors